Study guide
8.1 Introduction to ICH E6 GCP Principles (including R3 updates)
Certified Clinical Research Coordinator CCRC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Scientific Concepts and Research Design
1.1 Protocol Elements 1.2 Study Design and Objectives 1.3 Study Endpoints and Biostatistics
2 Chapter 2: Ethical Principles and Guidelines
2.1 Ethical Principles (Declaration of Helsinki, Belmont Report) 2.2 Informed Consent Process and Documentation 2.3 Vulnerable Populations and Assent
3 Chapter 3: IRB/IEC Oversight and Participant Safety
3.1 IRB/IEC Functions and Oversight 3.2 Adverse Event Classification and Reporting 3.3 Safety Monitoring and Safety Reporting
4 Chapter 4: Participant Rights and Ethics
4.1 Participant Rights and Confidentiality (HIPAA/GDPR) 4.2 Conflicts of Interest 4.3 Ethical Scenarios in Clinical Trials
5 Chapter 5: Product Development and Regulatory Framework
5.1 Drug and Device Development Phases 5.2 U.S. and International Regulatory Frameworks 5.3 Investigational Product Investigator's Brochure (IB)
6 Chapter 6: Investigational Product Accountability
6.1 Investigational Product Labeling and Storage 6.2 Investigational Product Receipt, Dispensing, and Accountability 6.3 Investigational Product Return and Destruction
7 Chapter 7: Regulatory Submissions and Actions
7.1 Regulatory Submissions (IND, NDA, IDE, PMA) 7.2 Regulatory Actions and Compliance 7.3 Pharmacokinetics and Pharmacodynamics in Product Development
8 Chapter 8: Clinical Trial Operations and GCP Principles
8.1 Introduction to ICH E6 GCP Principles (including R3 updates) 8.2 Investigator Responsibilities under GCP 8.3 Sponsor Responsibilities and Oversight
9 Chapter 9: Essential Documents and Site Qualification
9.1 Essential Documents (Pre-study, During, Post-study) 9.2 Site Selection and Qualification 9.3 Quality Management and Standard Operating Procedures (SOPs)
10 Chapter 10: Protocol Deviations and Amendments
10.1 Protocol Adherence and Compliance 10.2 Protocol Deviations and Violations 10.3 Protocol Amendments and Version Control
11 Chapter 11: Monitoring Visits and Audits
11.1 Monitoring Preparation and Visit Types 11.2 Monitoring Visits (SIV, IMV, COV) 11.3 Regulatory Inspections and Site Audits
12 Chapter 12: Study and Site Management - Startup
12.1 Site Startup Operations 12.2 Site Budget and Contract Management 12.3 Site Staffing, Training, and Documentation
13 Chapter 13: Enrollment and Recruitment
13.1 Enrollment Management and Strategies 13.2 Participant Recruitment and Retention 13.3 Participant Compensation and Ethics
14 Chapter 14: Daily Trial Coordination
14.1 Visit Scheduling and Logistics 14.2 Equipment Maintenance and Calibration 14.3 Specimen Handling and Shipping (IATA/dangerous goods)
15 Chapter 15: Quality Improvement and Site Closeout
15.1 Participant Safety Management 15.2 Quality Improvement and Site Audits Preparation 15.3 Study and Site Closeout Procedures
16 Chapter 16: Source Documentation and Case Report Forms
16.1 Source Documentation Standards (ALCOA-C) 16.2 Case Report Forms and eCRF Completion 16.3 Electronic Data Capture (EDC) Systems
17 Chapter 17: Data Management and Queries
17.1 Data Management Processes 17.2 Data Queries and Discrepancy Resolution 17.3 Data Correction and Audit Trails
18 Chapter 18: Data Privacy and Records Retention
18.1 Data Privacy and Confidentiality 18.2 Records Retention and Archiving 18.3 Compliance in Clinical Trial Informatics
8.1 Introduction to ICH E6 GCP Principles (including R3 updates)
Key Takeaways Explain This Topic AI
ICH GCP is an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve human participants.
The ICH E6(R3) revision emphasizes proportionality, leveraging technology, and adopting a risk-based approach to clinical trial quality management.
The rights, safety and well-being of participants are the most important considerations and prevail over the interests of science and society (principle 1.1).
Last updated: October 2026
Introduction to ICH E6 GCP Principles
Good Clinical Practice (GCP) is the universal standard for clinical trials. The International Council for Harmonisation (ICH) developed the ICH E6 guideline to provide a unified standard that facilitates the mutual acceptance of clinical trial data by regulatory authorities in ICH member countries and regions. As a Clinical Research Coordinator (CRC), a profound understanding of these principles is not just regulatory requirement—it is the bedrock of your daily professional conduct.
The Core Principles of GCP
ICH E6(R3) sets out 11 overarching principles. They are interdependent and should be considered together:
Ethics : Trials follow the ethical principles that have their origin in the Declaration of Helsinki. The rights, safety and well-being of participants are the most important considerations and prevail over the interests of science and society (principle 1.1). Foreseeable risks are weighed against anticipated benefits, a qualified physician (or dentist, or other qualified healthcare professional where local rules allow) has overall responsibility for trial-related medical care, and participants' confidentiality is protected.
Informed consent : Freely given informed consent is obtained and documented from every participant before participation, or from a legally acceptable representative for someone unable to consent; a minor gives assent as appropriate.
Independent review : Trials are reviewed by an IRB/IEC and conducted in compliance with the protocol that received its prior approval/favourable opinion.
Scientific soundness : Trials are scientifically sound and based on adequate, current nonclinical and clinical knowledge.
Qualified individuals : Everyone involved is qualified by education, training and experience for their tasks.
Quality by design : Quality is built into the scientific and operational design, focusing on the factors critical to quality.
Proportionality : Processes are proportionate to the risks to participants and the importance of the data, avoiding unnecessary burden.
A clear protocol : The protocol is clear, concise, scientifically sound and operationally feasible.
Reliable results : Data and records are fit for purpose and traceable, essential records are retained securely for the required period, and trials are registered and their results posted.
Clear roles : Roles and responsibilities are clear and documented; the sponsor may transfer and the investigator may delegate activities, but each keeps overall responsibility and oversight.
Investigational products : Products are manufactured under applicable GMP and managed according to the product specifications and the protocol, including handling, shipping, storage, dispensing, return and destruction.
E6(R2) set out 13 shorter principles; ACRP exams have used the E6(R3) set since July 15, 2026.
The Evolution to ICH E6(R3)
The clinical research landscape has transformed dramatically since the original ICH E6 guideline was adopted in 1996. The previous R2 update in 2016 introduced risk-based quality management. ICH finalized the E6(R3) principles and Annex 1 on January 6, 2025 and Annex 2 on June 3, 2026 (consolidated guideline adopted June 16, 2026), and ACRP adopted E6(R3) as the GCP reference for all certification examinations effective July 15, 2026 — replacing E6(R2). R3 modernizes the guideline to address the increasing diversity of clinical trial designs and data sources, including decentralized trials, pragmatic trials, and the incorporation of real-world data (RWD).
Key Updates in R3
Theme Description of R3 Emphasis Impact on CRC Role
Fit-for-Purpose Proportionality Emphasizes that quality measures should be proportionate to the risks inherent in the trial and the importance of the data collected. CRCs will see protocols that focus intense data collection on primary endpoints and critical safety data, rather than exhaustive, uniform data collection for all variables.
Embracing Technology Acknowledges the use of electronic systems, eConsent, wearables, and digital health technologies (DHTs) in trials. CRCs must be adept at training patients on using digital tools and ensuring data flows correctly from patient devices to the clinical database.
Decentralized Clinical Trials (DCTs) Provides a framework for conducting trials outside traditional clinical settings, improving patient access and diversity. Coordination will involve more remote monitoring, telehealth visits, and managing direct-to-patient shipping of investigational products.
Quality by Design (QbD) Proactively building quality into the scientific and operational design of the trial, rather than relying solely on retrospective checks. Focuses on preventing errors at the source through better protocol design and clear operational manuals.
Applying GCP in Daily Coordination
As a CRC, GCP principles are applied continuously:
During Screening : Ensuring the patient signs the IRB-approved consent form before any trial-specific procedures occur (Ethical principle).
During Visits : Documenting vital signs and adverse events exactly as they happened and entering them promptly into the Electronic Data Capture (EDC) system (Data integrity principle).
During Drug Dispensing : Storing the investigational product at the correct temperature and keeping precise logs of dispensation and return (investigational product principle).
Failure to adhere to GCP can result in regulatory warning letters, rejection of trial data, and, most importantly, harm to trial participants. The CRC serves as the vital link between the theoretical principles of GCP and their practical execution at the clinical site.